- Home
- CNNE vs IOVA Comparison
CNNE vs IOVA Comparison
Compare CNNE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- IOVA
- Stock Information
- Founded
- CNNE 2014
- IOVA 2007
- Country
- CNNE United States
- IOVA United States
- Employees
- CNNE N/A
- IOVA N/A
- Industry
- CNNE Restaurants
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNNE Consumer Discretionary
- IOVA Health Care
- Exchange
- CNNE Nasdaq
- IOVA Nasdaq
- Market Cap
- CNNE 1.2B
- IOVA 975.1M
- IPO Year
- CNNE N/A
- IOVA N/A
- Fundamental
- Price
- CNNE $18.70
- IOVA $2.22
- Analyst Decision
- CNNE Buy
- IOVA Buy
- Analyst Count
- CNNE 3
- IOVA 11
- Target Price
- CNNE $23.33
- IOVA $11.90
- AVG Volume (30 Days)
- CNNE 794.7K
- IOVA 14.9M
- Earning Date
- CNNE 08-11-2025
- IOVA 08-07-2025
- Dividend Yield
- CNNE 3.21%
- IOVA N/A
- EPS Growth
- CNNE N/A
- IOVA N/A
- EPS
- CNNE N/A
- IOVA N/A
- Revenue
- CNNE $437,200,000.00
- IOVA $241,525,000.00
- Revenue This Year
- CNNE N/A
- IOVA $67.40
- Revenue Next Year
- CNNE N/A
- IOVA $56.32
- P/E Ratio
- CNNE N/A
- IOVA N/A
- Revenue Growth
- CNNE N/A
- IOVA 636.99
- 52 Week Low
- CNNE $15.92
- IOVA $1.64
- 52 Week High
- CNNE $22.36
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- CNNE 41.76
- IOVA 43.38
- Support Level
- CNNE $18.39
- IOVA $2.21
- Resistance Level
- CNNE $18.82
- IOVA $2.76
- Average True Range (ATR)
- CNNE 0.50
- IOVA 0.21
- MACD
- CNNE 0.09
- IOVA -0.04
- Stochastic Oscillator
- CNNE 53.35
- IOVA 26.19
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.